Coherus Oncology Partners with Janssen for Phase 1b Prostate Cancer Study

summarizeSummary

Coherus Oncology announced a clinical supply agreement with Janssen to evaluate its investigational antibody, tagmokitug, in a Phase 1b study for prostate cancer.

check_boxKey Events

• Clinical Supply Agreement with Janssen

  Coherus Oncology, Inc. entered into a clinical supply agreement with Janssen Research & Development, LLC.

• Phase 1b Study for Prostate Cancer

  The agreement is to evaluate tagmokitug (CHS-114) in combination with pasritamig in a Phase 1b clinical study for metastatic castration-resistant prostate cancer (mCRPC).

• Coherus to Sponsor Trial

  Coherus Oncology will be the sponsor of the Phase 1b clinical trial, with Janssen providing pasritamig.

• Retained Commercial Rights

  Both companies retain all commercial rights to their respective compounds, whether as monotherapy or combination treatments.

auto_awesomeAnalysis

This clinical supply agreement with Janssen Research & Development is a significant positive development for Coherus Oncology, advancing its investigational anti-CCR8 antibody, tagmokitug (CHS-114), into a Phase 1b study for metastatic castration-resistant prostate cancer. Collaborating with a major pharmaceutical company like Janssen validates Coherus's pipeline asset and provides resources for clinical development. While Coherus will sponsor the trial, the partnership leverages Janssen's T-cell engaging bispecific antibody, pasritamig, potentially accelerating the development of a novel combination therapy. This news follows recent financing activity, including an ATM offering, suggesting the company is actively deploying capital to advance its clinical programs.